Explore

Rapid Read Rapid Read
Curebound Expands Leadership Team to Boost Cancer Research Efforts

Curebound Expands Leadership Team to Boost Cancer Research Efforts

Curebound, a cancer research accelerator based in San Diego, has announced the appointment of three key executives to its leadership team. Mary Meyer joins as Chief Advancement Officer, Scotty Cadet, Ph.D., as Chief Scientific Officer and Vice President of Research, and Leena Gupta as Chief Financial Officer. These appointments aim to enhance Curebound's fundraising, scientific leadership, and financial strategy. Meyer brings extensive experience in philanthropy, Cadet in cancer research and drug development, and Gupta in financial management for nonprofits. The new team is expected to drive Curebound's mission of advancing early cancer detection and personalized therapies.
Rapid Read Rapid Read
Cooper University Health and MD Anderson Receive $100M Donation for Expansion

Cooper University Health and MD Anderson Receive $100M Donation for Expansion

Cooper University Health and its partner, MD Anderson Cancer Center, have received a $100 million donation to support their ongoing expansion efforts. This significant gift will aid in the $3 billion expansion project at Cooper's main campus in Camden, New Jersey. The expansion aims to enhance the facilities and services offered by the health system, which is a key provider of cancer care in the region. The donation is expected to accelerate the development of new infrastructure and technology, improving patient care and expanding access to advanced medical treatments.
Rapid Read Rapid Read
New Human Tissue Model Advances Glioblastoma Research

New Human Tissue Model Advances Glioblastoma Research

Researchers at the University Hospital Bonn and the University of Bonn have developed a new model, Core2Edge, to study glioblastoma, an aggressive brain tumor. This model, based entirely on human tissue, captures the infiltration zones at the tumor margin, allowing for the investigation of invasive tumor cells and the assessment of new drug candidates without animal testing. Glioblastoma is known for its invasive behavior, with tumor cells migrating into healthy brain tissue, making it difficult to completely remove and leading to recurrence. The Core2Edge model combines glioblastoma organoids with human brain tissue, enabling researchers to track tumor spread and study the genetic activity of individual tumor cells.
Rapid Read Rapid Read
UNC Researchers Develop Light-Activated Cancer Treatment to Minimize Side Effects

UNC Researchers Develop Light-Activated Cancer Treatment to Minimize Side Effects

Researchers at the University of North Carolina at Chapel Hill are exploring a novel approach to cancer treatment that aims to reduce the chronic side effects often associated with traditional therapies. Led by Brianna Vickerman, a research assistant professor at the UNC Eshelman School of Pharmacy, the team is developing a method that uses light to activate cancer drugs only at the disease site. This technique involves encapsulating existing medications into carriers that circulate through the body without affecting healthy tissues. When the disease area is illuminated, the carriers release the drug precisely where needed. This approach builds on previous research involving light-controlled drug delivery for cardiovascular diseases. The project recently received a two-year commercialization-focused innovation grant to further test the technology in cancer models, with the ultimate goal of clinical development.
Trendline Trendline
Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update

Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update

Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update
Trendline Trendline
Xiomara Arroyo's Leadership Journey Highlighted by Service and Community Involvement

Xiomara Arroyo's Leadership Journey Highlighted by Service and Community Involvement

Xiomara Arroyo's Leadership Journey Highlighted by Service and Community Involvement
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Rapid Read Rapid Read
U.S. Department of Labor Partners with Huntington Ingalls to Boost Maritime Workforce

U.S. Department of Labor Partners with Huntington Ingalls to Boost Maritime Workforce

The U.S. Department of Labor has formed a partnership with Huntington Ingalls Industries, a major military shipbuilder, to enhance the maritime workforce through expanded pre-apprenticeship opportunities. This initiative aims to support the Trump administration's efforts to revitalize America's industrial base. Acting Secretary of Labor Keith Sonderling highlighted the dual benefits of this partnership: providing hope to young individuals in pre-apprenticeship programs and revitalizing the maritime workforce, which is crucial for domestic supply chains. The collaboration includes plans to utilize the San Diego Job Corps Center to establish a maritime-focused training site, offering career and technical education essential for shipbuilding roles. Discussions between department officials and Huntington Ingalls executives took place in San Diego, exploring workforce development opportunities across southern California, including integrating three additional Job Corps Centers to expedite the development of ski...
Rapid Read Rapid Read
Gene Editing Enhances Immune Response to Prostate Cancer in Preclinical Study

Gene Editing Enhances Immune Response to Prostate Cancer in Preclinical Study

Researchers from Duke University and the University of Rochester have developed a gene-editing technology that could significantly improve the effectiveness of immunotherapy for prostate cancer. The study, published in Nature Biomedical Engineering, utilized CRISPR technology to modify the way prostate cancer cells process messenger RNA (mRNA). This alteration made the tumors more visible to the immune system, allowing for a more robust immune response. In preclinical trials with mice, the treatment increased the infiltration of immune cells into tumors, enhancing the efficacy of immune checkpoint therapy. The research builds on previous findings that certain cancers evade immune detection by shortening mRNA molecules, which affects protein production and immune recognition.
Trendline Trendline
MrBeast and LeBron James Collaborate to Support Kids Battling Cancer in Akron

MrBeast and LeBron James Collaborate to Support Kids Battling Cancer in Akron

MrBeast and LeBron James Collaborate to Support Kids Battling Cancer in Akron
Rapid Read Rapid Read
CRISPR Technology Enhances Prostate Cancer Immunotherapy Effectiveness

CRISPR Technology Enhances Prostate Cancer Immunotherapy Effectiveness

Researchers have developed a CRISPR-based RNA targeting technology that makes prostate cancer cells more susceptible to immunotherapy. Prostate tumors are typically 'immune cold,' attracting few T cells, which are crucial for immunotherapy to work. The new technology alters RNA within cancer cells, making them more visible to immune cells. This approach has shown improved responses in mice, with more immune cells infiltrating and attacking the tumors. The study, published in Nature Biomedical Engineering, highlights the potential of this method to enhance existing immunotherapies for prostate and other immune-cold tumors.
Rapid Read Rapid Read
CRISPR Technology Enhances Prostate Cancer Immunotherapy by Increasing Tumor Vulnerability

CRISPR Technology Enhances Prostate Cancer Immunotherapy by Increasing Tumor Vulnerability

Researchers have developed an experimental RNA targeting technology using CRISPR that may significantly improve the effectiveness of immunotherapy in treating prostate cancer. Prostate tumors are typically 'immune cold,' meaning they attract few T cells, which are crucial for the success of immunotherapy. The new CRISPR-based tool modifies RNA within prostate cancer cells, making the tumors more visible to immune cells. This advancement was detailed in a study published in Nature Biomedical Engineering, where the technology was shown to enhance the response of prostate tumors to immune checkpoint therapy in mice. The study, led by scientists from Duke University School of Medicine, demonstrated that the CRISPR tool could restore the MHC-1 complex, a molecular signal that helps T cells recognize tumor cells, thereby increasing the effectiveness of immunotherapy.